Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease

Next Previous
Trial Profile

International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Mar 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vascular endothelial growth factor-165 gene therapy (Neovasculgen) (Primary)
  • Indications Peripheral ischaemia
  • Focus Therapeutic Use
  • Acronyms NVG-LIGHT
  • Sponsors Human Stem Cells Institute

    • Most Recent Events

    • 03 Jan 2017 Status changed from active, no longer recruiting to completed,according to the results published in the American Journal of Cardiovascular Drugs.
    • 03 Jan 2017 Results aseesing safety and efficacy of gene therapy ,also comparing the results of this study with previous phase II/III study published in the American Journal of Cardiovascular Drugs (2016).
    • 27 Feb 2015 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top